The Complexities of HER2-low Disease and why Precision isn’t just about Biomarkers, it’s about Mindset – Community Health Media
Community Health Media shared a post on LinkedIn:
“What happens when HER2-targeted therapies like T-DXd challenge not only clinical expectations, but also the very framework of breast cancer classifications?
Drs. Paolo Tarantino and Jason A. Mouabbi explore how evolving HER2 definitions are reshaping patient care, trial design, and what we consider “treatable.”
Their conversation dives into the complexities of HER2-low disease and why precision isn’t just about biomarkers—it’s about mindset.
Watch the full CHM Conversations episode for deeper insight into the shifting landscape of HER2+ breast cancer.”
Paolo Tarantino, Advanced Research Fellow at Dana-Farber Cancer Institute and Harvard Medical School, reshared the post on Linkedin, adding:
“How will physicians translate the results of DESTINY-Breast09 into clinical practice?
Will we treat HER2+ MBC with indefinite T-DXd/P, or stop chemo at a certain point?
Fun discussion with Jason A. Mouabbi.”
More posts featuring Paolo Tarantino.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023